MDMA ("Ecstasy"), PTSD, Psychotherapy & MAPS | Berra Yazar-Klosinski | #26

Nick talks to Dr. Berra Yazar-Klosinski, the Chief Science Officer for the Multidisciplinary Association for Psychedelic Studies  (MAPS). Berra talked about the results of MAPS' recent Phase III clinical trials for treating severe PTSD, how these studies are conducted, and what we know about the underlying biology of Post-Traumatic Stress Disorder (PTSD) and the drug MDMA. 

USEFUL LINKS:
Download the podcast & follow Nick at his website
[www.nickjikomes.com]

Support the show on Patreon & get early access to episodes
[https://www.patreon.com/nickjikomes]

Sign up for the weekly Mind & Matter newsletter
[http://eepurl.com/hFlc7H]

Try MUD/WTR, a mushroom-based coffee alternative
[https://www.mudwtr.com/mindmatter]
Discount Code ($5 off) = MINDMATTER

Organize your digital highlights & notes w/ Readwise (2 months free w/ subscription)
[https://readwise.io/nickjikomes/]

Start your own podcast (get $20 Amazon gift card after signup)
[https://www.buzzsprout.com/?referrer_id=1507198]

Buy Mind & Matter T-Shirts
[https://www.etsy.com/shop/OURMIND?ref=simple-shop-header-name&listing_id=1036758072&section_id=34648633]

Connect with Nick Jikomes on Twitter
[https://twitter.com/trikomes]
​​​
Learn more about our podcast sponsor, Dosist
[https://dosist.com/]

ABOUT Nick Jikomes:
Nick is a neuroscientist and podcast host. He is currently Director of Science & Innovation at Leafly, a technology startup in the legal cannabis industry. He received a Ph.D. in Neuroscience from Harvard University and a B.S. in Genetics from the University of Wisconsin-Madison.

Support the show (https://www.patreon.com/nickjikomes)

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit mindandmatter.substack.com/subscribe